Information Provided By:
Fly News Breaks for January 4, 2016
LGND
Jan 4, 2016 | 08:23 EDT
After Ligand (LGND) disclosed a Captisol supply agreement with Gilead (GILD) for an Ebola drug and potentially others, Roth Capital analyst Joseph Pantginis said he expects more announcements of this type to come and views Ligand as strongly positioned for continued growth. The analyst keeps a Buy rating and $146 price target on Ligand shares.
News For LGND From the Last 2 Days
There are no results for your query LGND